BackALK-Abelló A/S Overview

ALK-Abelló A/S EBIT

ALK-Abelló A/S's EBIT is $1.9B, below the Healthcare sector average of $1.1T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$482.00M
↑ 13.95% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$1.90B
↑ 26.28% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

ALK-Abelló A/S (AKBLF) FAQ

The latest EBIT for AKBLF is $1.9B as of September 2026. That compares with $1.5B in the prior-year period — up 26.3% year over year. That is below the Healthcare sector average of $1.1T. Investors often review this figure alongside ALK-Abelló A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, AKBLF's EBIT moved from $1.5B to $1.9B — a 26.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ALK-Abelló A/S's operating scale or balance-sheet position.

Against Healthcare companies, AKBLF currently prints $1.9B for EBIT, while the sector average sits near $1.1T. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at ALK-Abelló A/S's growth, margins, and balance sheet.

A EBIT figure of $1.9B for AKBLF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.1T. Explore the charts below for those layers of context.

After noting AKBLF's EBIT ($1.9B), review year-over-year change from $1.5B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers